An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive survival outcomes in patients with resected pancreatic and colorectal cancers, according to final results from the phase I AMPLIFY-201 trial.

The vaccine doesn't prevent cancer from happening in the first place, but an early-phase trial found it could reduce the odds of recurrence.

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small UCLA clinical trial suggests.